Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

Xinxin Song; Zhuan Zhou; Rui Kang; Daolin Tang

doi:10.1080/2162402X.2022.2141978

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

Xinxin Song, Zhuan Zhou, Rui Kang, Daolin Tang

Research output: Contribution to journal › Article › peer-review

Abstract

The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.

Original language	English (US)
Article number	2141978
Journal	OncoImmunology
Volume	11
Issue number	1
DOIs	https://doi.org/10.1080/2162402X.2022.2141978
State	Published - 2022

Keywords

bispecific T cell engagers
KRAS-G12C

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.1080/2162402X.2022.2141978

Cite this

@article{ae09a6ec50cb444d838c42f13eb4b593,

title = "Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy",

abstract = "The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.",

keywords = "bispecific T cell engagers, KRAS-G12C",

author = "Xinxin Song and Zhuan Zhou and Rui Kang and Daolin Tang",

note = "Funding Information: Research by D.T. and R.K. was supported by grants from the National Institutes of Health [R01CA160417, R01CA229275, and R01CA211070]. Publisher Copyright: {\textcopyright} 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2022",

doi = "10.1080/2162402X.2022.2141978",

language = "English (US)",

volume = "11",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

AU - Song, Xinxin

AU - Zhou, Zhuan

AU - Kang, Rui

AU - Tang, Daolin

N1 - Funding Information: Research by D.T. and R.K. was supported by grants from the National Institutes of Health [R01CA160417, R01CA229275, and R01CA211070]. Publisher Copyright: © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.

PY - 2022

Y1 - 2022

N2 - The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.

AB - The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selectively eliminate G12Ci-resistant cells.

KW - bispecific T cell engagers

KW - KRAS-G12C

UR - http://www.scopus.com/inward/record.url?scp=85141412804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141412804&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2022.2141978

DO - 10.1080/2162402X.2022.2141978

M3 - Article

C2 - 36338145

AN - SCOPUS:85141412804

SN - 2162-4011

VL - 11

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2141978

ER -

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this